^
Association details:
| Biomarker: | STAG2 underexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
Excerpt:
Knockdown of STAG2 also resulted in increases of basal pERK levels and reduction of the ability of dabrafenib to inhibit ERK phosphorylation in these cells (Fig. 2b). However, phospho-Akt and phospho-S6 levels were not affected by knockdown of STAG2. Similarly, inducible expression of an independent shRNA against STAG2 also decreased the sensitivity to either dabrafenib or vemurafenib BRAFi in SKMEL28, A375 and M14 cells.
DOI:
10.1038/nm.4155
